SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-033484
Filing Date
2024-03-19
Accepted
2024-03-19 16:15:31
Documents
98
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K tsha-20231231.htm   iXBRL 10-K 2837636
2 EX-23.1 tsha-ex23_1.htm EX-23.1 2769
3 EX-31.1 tsha-ex31_1.htm EX-31.1 15284
4 EX-31.2 tsha-ex31_2.htm EX-31.2 15299
5 EX-32.1 tsha-ex32_1.htm EX-32.1 9156
6 EX-32.2 tsha-ex32_2.htm EX-32.2 8894
7 EX-97.1 tsha-ex97_1.htm EX-97.1 60988
8 GRAPHIC img38674483_0.jpg GRAPHIC 29782
9 GRAPHIC img38674483_1.jpg GRAPHIC 76090
10 GRAPHIC img38674483_2.jpg GRAPHIC 28410
11 GRAPHIC img38674483_3.jpg GRAPHIC 29775
12 GRAPHIC img38674483_4.jpg GRAPHIC 82564
13 GRAPHIC img38674483_5.jpg GRAPHIC 27437
14 GRAPHIC img38674483_6.jpg GRAPHIC 24306
15 GRAPHIC img38674483_7.jpg GRAPHIC 54319
  Complete submission text file 0000950170-24-033484.txt   12845308

Data Files

Seq Description Document Type Size
16 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tsha-20231231.xsd EX-101.SCH 1854455
102 EXTRACTED XBRL INSTANCE DOCUMENT tsha-20231231_htm.xml XML 1984337
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39536 | Film No.: 24763415
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)